P2RX7 Enhances Tumor Control by CD8+T Cells in Adoptive Cell Therapy

Kelsey M. Wanhainen, Changwei Peng, Maggie H. Zhou, Bruna De Gois MacEdo, Stephen O'Flanagan, Tingyuan Yang, Ameeta Kelekar, Brandon J. Burbach, Henrique Borges Da Silva, Stephen C. Jameson

Research output: Contribution to journalArticlepeer-review


Expression of the purinergic receptor P2RX7 by CD8+ T cells promotes the generation of memory populations following acute infections. However, data suggest that P2RX7 may limit the efficacy of antitumor responses. Herein, we show that P2RX7 is beneficial for optimal melanoma control in a mouse CD8+ T-cell adoptive transfer model. Tumor-specific P2rx7-/- CD8+ T cells exhibited impaired mitochondrial maintenance and function but did not display signs of overt exhaustion early in the antitumor response. However, as the tumor burden increased, the relative frequency of P2RX7-deficient CD8+ T cells declined within the tumor; this correlated with reduced proliferation, increased apoptosis, and mitochondrial dysfunction. Extending these studies, we found that the transient in vitro stimulation of P2RX7 using the ATP analogue BzATP led to enhanced B16 melanoma control by CD8+ T cells. These findings are in keeping with the concept that extracellular ATP (eATP) sensing by P2RX7 on CD8+ T cells is required for their ability to efficiently eliminate tumors by promoting mitochondrial fitness and underscore the potential for P2RX7 stimulation as a novel therapeutic treatment to enhance tumor immunotherapy.

Original languageEnglish (US)
Pages (from-to)871-884
Number of pages14
JournalCancer Immunology Research
Issue number7
StatePublished - Jul 2022

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'P2RX7 Enhances Tumor Control by CD8+T Cells in Adoptive Cell Therapy'. Together they form a unique fingerprint.

Cite this